<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6913923</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0007915</article-id><article-id pub-id-type="publisher-id">PNTD-D-19-00507</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Hemorrhagic Fever with Renal Syndrome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Nucleoproteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Immunologic Techniques</subject><subj-group><subject>Immunoassays</subject><subj-group><subject>Enzyme-Linked Immunoassays</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Bioinformatics</subject><subj-group><subject>Sequence Analysis</subject><subj-group><subject>Sequence Alignment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antigens</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antigens</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antigens</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antigens</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antigens</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Bioinformatics</subject><subj-group><subject>Sequence Analysis</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Identification and validation of specific B-cell epitopes of hantaviruses associated to hemorrhagic fever and renal syndrome</article-title><alt-title alt-title-type="running-head">Identification of B-cell linear epitopes present on Seoul orthohantavirus nucleoprotein</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Conte</surname><given-names>Fernando de Paiva</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tinoco</surname><given-names>Bianca Corr&#x000ea;a</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9699-3320</contrib-id><name><surname>Santos Chaves</surname><given-names>Thiago</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Oliveira</surname><given-names>Renata Carvalho</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Figueira Mansur</surname><given-names>Janaina</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mohana-Borges</surname><given-names>Ronaldo</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Lemos</surname><given-names>Elba Regina Sampaio</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Neves</surname><given-names>Patricia Cristina da Costa</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9772-849X</contrib-id><name><surname>Rodrigues-da-Silva</surname><given-names>Rodrigo Nunes</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Laboratory of Monoclonal Antibodies Technology, Immunobiological Technology Institute, FIOCRUZ, Rio de Janeiro, Brazil</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Laboratory of Hantaviroses and Rickettsioses, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Laborat&#x000f3;rio Gen&#x000f4;mica Estrutural, Instituto de Biof&#x000ed;sica Carlos Chagas Filho (IBCCF), Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, Brazil</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Samy</surname><given-names>Abdallah M.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Faculty of Science, Ain Shams University (ASU), EGYPT</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>Rodrigo.nunes@bio.fiocruz.br</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>13</volume><issue>12</issue><elocation-id>e0007915</elocation-id><history><date date-type="received"><day>8</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Conte et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Conte et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pntd.0007915.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Orthohantavirus infection is a neglected global health problem affecting approximately 200,000 people/year, spread by rodent hosts and associated to fatal human diseases, such as hemorrhagic fever with renal syndrome (HFRS) and orthohantavirus cardiopulmonary syndrome (HCPS). Circulation of HFRS-associated orthohantaviruses, such as Seoul, Gou, Amur, Dobrava and Hantaan, are supposed to be restricted to Eurasian countries even though their hosts can be a worldwide distribution. Few confirmed HFRS orthohantavirus infections in humans have been reported in American countries, but due to lower medical awareness of the symptoms of this zoonosis, it could be associated to viral underreporting or to misdiagnosis with several tropical hemorrhagic diseases. Serological evidence of orthohantavirus infections, using enzyme-linked immunosorbent assay for the presence of immunoglobulin M and G against recombinant nucleoprotein protein, remains as an essential assay for viral surveillance. In this study, we aimed to identify <italic>in silico</italic> immunogenic B-cell linear epitopes present on orthohantavirus nucleoprotein that are exclusive to HFRS-related species.</p></sec><sec id="sec002"><title>Methodology/Principal findings</title><p><italic>In silico</italic> analysis were performed using <italic>Seoul orthohantavirus</italic> nucleoprotein (SHNP) sequence as a model. Linear B-cell-epitopes on SHNP and its immunogenicity were predicted by BepiPred-2.0 and Vaxijen algorithms, respectively. The conservancy of predicted epitopes was compared with the most clinically relevant HFRS or HCPS-associated orthohantavirus, aiming to identify specific sequences from HFRS-orthohantavirus. Peptide validation was carried out by ELISA using Balb/c mice sera immunized with purified recombinant rSHNP. Peptides cross-reactivity against HCPS orthohantavirus were evaluated using immunized sera from mice injected with recombinant Juquitiba orthohantavirus nucleoprotein (rJHNP).</p></sec><sec id="sec003"><title>Conclusion/Significance</title><p><italic>In silico</italic> analysis revealed nine potential immunogenic linear B-cell epitopes from SHNP; among them, SHNP<sub>(G72-D110)</sub> and SHNP<sub>(P251-D264)</sub> showed a high degree of sequence conservation among HFRS-related orthohantavirus and were experimentally validated against rSHNP-IMS and negatively validated against rJHNP-IMS. Taken together, we identified and validated two potential antigenic B-cell epitopes on SHNP, which were conserved among HFRS-associated orthohantavirus and could be applied to the development of novel immunodiagnostic tools for orthohantavirus surveillance.</p></sec></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Orthohantaviruses are the etiological agents of serious rodent-borne neglected human diseases named as hemorrhagic fever with renal syndrome (HFRS) and orthohantavirus cardiopulmonary syndrome (HCPS). These distinct clinical manifestations of disease are related to specific orthohantavirus species and it is believed that HFRS-associated orthohantavirus mainly circulate into Old World (Asia and Europe) whereas HCPS-associated orthohantaviruses are predominant into New World countries (Americas). However, since <italic>Seoul orthohantavirus</italic>, associated with HFRS, was isolated in America and its natural host (<italic>Rattus norvegicus</italic>) are widely distributed around the world, it raised the question if the viral underreporting is associated to lower medical awareness of the symptoms or if it is associated to misdiagnosis with other tropical hemorrhagic diseases (leptospirosis, yellow fever). In this context, considering that the HFRS are clinically indistinguishable from order hemorrhagic diseases, and that serological tests are predominantly based on serology tests against nucleoprotein, a highly conserved protein among different orthohantavirus, we hypothesize that current available tests do not detect all HFRS-associated orthohantavirus. In this sense; we aimed to identify B-cell linear epitopes exclusively conserved on HFRS-associated orthohantavirus nucleoprotein, using a combination of <italic>in silico</italic> and experimental approaches, to identify targets that could be applied in the development of novel immunodiagnostic tools able to identify different HFRS orthohantavirus species.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003593</institution-id><institution>Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico</institution></institution-wrap></funding-source><award-id>404762/2016-6</award-id><principal-award-recipient><name><surname>de Lemos</surname><given-names>Elba Regina Sampaio</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado do Rio de Janeiro (BR)</institution></funding-source><award-id>E-26/260.041/2019</award-id><principal-award-recipient><name><surname>Tinoco</surname><given-names>Bianca Corr&#x000ea;a</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by Institute of Immunobiological Technology, Oswaldo Cruz Foundation (Fiocruz) and by Federal University of Rio de Janeiro (UFRJ). ERSL is recipient of Conselho Nacional de Pesquisa e Desenvolvimento (CPNq) -Universal research grants (404762-2016-6 - <ext-link ext-link-type="uri" xlink:href="http://cnpq.br/">http://cnpq.br/</ext-link>). BCT is recipient of FAPERJ technological initiation scholarship (E-26/260.041/2019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript.</p></notes></front><body><sec sec-type="intro" id="sec004"><title>Introduction</title><p>Orthohantaviruses belong to genus <italic>Orthohantavirus</italic>, of the family <italic>Hantaviridae</italic>, which comprises a diverse group of infectious negative-sense single-stranded RNA viruses. They are zoonotic in nature and transmitted to humans through the inhalation of contaminated aerosols present in the excreta, saliva, and urine of infected rodent animals [<xref rid="pntd.0007915.ref001" ref-type="bibr">1</xref>].</p><p>Orthohantavirus infections are a neglected global health problem, affecting approximately 200,000 people/year [<xref rid="pntd.0007915.ref001" ref-type="bibr">1</xref>], and are associated with serious and fatal diseases in humans, such as hemorrhagic fever with renal syndrome (HFRS) and orthohantavirus cardiopulmonary syndrome (HCPS). The clinical manifestations of the disease are correlated to orthohantavirus species/genotypes and also it is intimately associated with rodent reservoirs that have a specific geographical distribution worldwide. HFRS is caused by Old World orthohantaviruses such as Hantaan, Amur and Gou virus in Asia and by <italic>Seoul orthohantavirus</italic> (SEOV) worldwide. Besides, orthohantavirus New World species such as <italic>Sin Nombre orthohantavirus</italic> in North America, and Andes, <strike>Juquitiba,</strike> Laguna Negra, and other related virus in Latin America, such as Juquitiba genotype are responsible for the more severe HCPS [<xref rid="pntd.0007915.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pntd.0007915.ref005" ref-type="bibr">5</xref>].</p><p>Among hantavirus associated to HFRS, the SEOV is spread worldwide by <italic>Rattus norvegicus</italic> and <italic>Rattus rattus</italic>, two rodent species present on the five continents, which are also implicated in leptospirosis outbreaks [<xref rid="pntd.0007915.ref006" ref-type="bibr">6</xref>]. In Americas, we highlight that SEOV has already been detected in both rodents, <italic>R</italic>. <italic>norvegicus</italic> and <italic>R</italic>. <italic>rattus</italic>, in Argentina [<xref rid="pntd.0007915.ref007" ref-type="bibr">7</xref>], United States [<xref rid="pntd.0007915.ref008" ref-type="bibr">8</xref>] and Brazil [<xref rid="pntd.0007915.ref007" ref-type="bibr">7</xref>, <xref rid="pntd.0007915.ref009" ref-type="bibr">9</xref>]. Nonetheless, few cases of HFRS have been reported in Brazil [<xref rid="pntd.0007915.ref010" ref-type="bibr">10</xref>], where this syndrome could be misdiagnosed as other tropical infectious diseases like dengue, yellow fever and leptospirosis. This data combined with the absence of a specific surveillance for SEOV and others HFRS- associated orthohantavirus in Western countries, and with the inability to confirm cases on site, by laboratory diagnosis, make urgent the development of new diagnostic tools.</p><p>In this context, the orthohantavirus nucleoprotein (NP) is the major antigen that elicits early serological responses in infected humans and has been used as a biomarker to develop antibodies for epidemiological surveillance in regions where various orthohantavirus species cocirculate [<xref rid="pntd.0007915.ref011" ref-type="bibr">11</xref>, <xref rid="pntd.0007915.ref012" ref-type="bibr">12</xref>]. This protein consists of about 429-amino acid residues, is largely expressed in initial infection and is highly conserved among orthohantavirus [<xref rid="pntd.0007915.ref013" ref-type="bibr">13</xref>]. Since the aminoacid sequence of HFRS-associated orthohantavirus are not identical, previous works tried to develop immunochromatographic antibody tests using a combination of different orthohantavirus nucleoproteins [<xref rid="pntd.0007915.ref014" ref-type="bibr">14</xref>] or a combination of nucleoprotein and other peptides [<xref rid="pntd.0007915.ref015" ref-type="bibr">15</xref>] in order to detect all Eurasian pathogenic orthohantavirus infections. Recently, Kalaiselvan and collaborators suggested that <italic>in silico</italic> predicted B-cell epitopes on NP could be used to identify specific markers to the HFRS [<xref rid="pntd.0007915.ref016" ref-type="bibr">16</xref>] and HCPS-associated orthohantavirus [<xref rid="pntd.0007915.ref017" ref-type="bibr">17</xref>]. However, the experimental validation of these epitopes remains unexplored. By this way, this study aimed to predict B-cell epitopes on Seoul orthohantavirus nucleoprotein (SHNP), that are exclusively conserved among HFRS-associated orthohantavirus, using a combination of the three most used prediction algorithms, and to validate the epitopes predicted as specific to SEOV or as conserved among HFRS orthohantavirus, against sera of mice immunized with recombinant SHNP.</p></sec><sec sec-type="materials|methods" id="sec005"><title>Methods</title><sec id="sec006"><title>Sequence data</title><p>To predict possible antigenic properties and the three-dimensional (3D) structure of SHNP (Seoul virus BjHD01, Accession Number AY627049.2) using bioinformatic tools, the entire sequence of SHNP (NCBI ID: AAT45728.1) was downloaded from the NCBI website (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein">www.ncbi.nlm.nih.gov/protein</ext-link>) and used for analyses.</p></sec><sec id="sec007"><title><italic>In silico</italic> prediction of linear B-cell epitopes on seoul hantavirus nucleoprotein</title><p>To predict linear B-cell epitopes on the entire sequence of SHNP we used a combination of two prediction algorithms: BepiPred 2.0 (<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/BepiPred/">http://www.cbs.dtu.dk/services/BepiPred/</ext-link>) and Vaxijen (<ext-link ext-link-type="uri" xlink:href="http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html">http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html</ext-link>).</p><p>Firstly, the prediction of linear B-cell epitopes was carried out using the web server Bepipred 2.0, which uses a Random Forest algorithm trained on epitopes and non-epitope amino acids determined by crystal structures from a protein sequence. For each FASTA input sequence, the server outputs a prediction score for each amino acid. To determine potential B-cell linear epitopes, we utilized the recommended cutoff of 0.5, ensuring a specificity of 57% and sensibility of 59% [<xref rid="pntd.0007915.ref018" ref-type="bibr">18</xref>]. Therefore, the Bepipred score represents the average of the scores of at least nine consecutive amino acids above the cut-off. Sequences with BepiPred score above 0.5 were considered as potential linear B-cell epitopes and analyzed by Vaxijen.</p><p>VaxiJen is the first server for alignment-independent prediction of protective antigens. It was developed to allow antigens classification solely based on the physicochemical properties of proteins without recourse to sequence alignment. Bacterial, viral and tumour protein datasets were used to derive models for prediction of whole protein antigenicity, showing prediction accuracy from 70% to 89% [<xref rid="pntd.0007915.ref019" ref-type="bibr">19</xref>]. To evaluate the antigenicity of predicted epitopes, we used the default cut-off (0.4), suggested to viral antigens. Therefore, sequences with BepiPred score above 0.5 and Vaxijen score above 0.4 were considered potential linear B-cell epitopes and evaluated to specificity.</p></sec><sec id="sec008"><title>Evaluation of conservation degree of linear B-cell epitopes</title><p>Sequences identified as potential linear B-cell epitopes were aligned to nucleoprotein sequences of orthohantavirus associated to HFRS or HCPS for similarity comparison. Gou virus (GOUV, Uniprot ID: Q8V6A4); Hantaan virus (HTNV, Uniprot ID: P05133); Amur virus (AMRV, Uniprot ID: A1YQ86), Dobrava-Belgrade virus (DOBV, Uniprot ID: D2IFH1) and Puumala virus (PUUV, Uniprot ID P19475) were the HFRS selected species for the similarity evaluation. Orthohantavirus Juquitiba genotype (JUQV, Uniprot ID A0A248QEV0), Andes virus (ANDV, Uniprot ID: O36307), Laguna Negra virus (LANV, Uniprot ID: C5IAR6) and Sin Nombre virus (SNV; Uniprot ID: Q89462) were the HCPS selected viruses for the conservation degree comparison of the predicted epitopes. All NP sequences were aligned and compared to SHNP and the degree of conservation among them were evaluated by BioEdit Sequence Alignments Editor, Version 7.0.9.0 [<xref rid="pntd.0007915.ref020" ref-type="bibr">20</xref>].</p></sec><sec id="sec009"><title>Peptide synthesis</title><p>After consensus analysis of the <italic>in silico</italic> prediction tools, the selected sequences were synthesized by fluorenylmethoxycarbonyl (F-moc) solid-phase chemistry [<xref rid="pntd.0007915.ref021" ref-type="bibr">21</xref>, <xref rid="pntd.0007915.ref022" ref-type="bibr">22</xref>] (GenOne Biotechnologies, Brazil). Analytical chromatography of the peptide demonstrated a purity of &#x0003e;95% and mass spectrometric analysis also indicated estimated masses corresponding to the molecular masses of the peptides (SHNP<sub>(G72-D110)</sub>: 4211.49 Da, SHNP<sub>(P251-D264)</sub>: 1396.51 Da and SHNP<sub>(I266-A283)</sub>: 2030.32 Da).</p></sec><sec id="sec010"><title>Expression and purification of the recombinant hantavirus nucleoproteins</title><p>The cDNA codifying the Seoul or Juquitiba orthohantavirus genotypes nucleoprotein (429 and 428 amino acids, respectively) were cloned into plasmid pET21a(+) to express the nucleoprotein with a six-histidine tag on its C-terminus (Genscript, USA). This construct was used to transform into BL21DE3 strain from <italic>E</italic>. <italic>coli</italic> and the protein was expressed during 4 h upon the addition of 1 mM IPTG. The cells were pelleted by centrifugation at 5,000 <italic>g</italic> for 15 min at 4 <sup>o</sup>C and stored at -80 <sup>o</sup>C until use. The cellular pellet was resuspended using the following buffer composition: 50 mM sodium phosphate, pH 6,0, 500 mM NaCl, 1 mM &#x003b2;-mercaptoethanol, 5% glycerol, 10 mM imidazol, EDTA-free protease inhibitor cocktail (Roche, Germany). The cellular lysis was obtained by the addition of 1 mg/mL lysozyme under stirring at 4&#x000b0;C for 30 min, Next, 20 &#x003bc;g/mL DNase and 2 mM MgCl<sub>2</sub> were added and the solution was incubated for more 30 min. The lysate was sonicated 15 times, alternating 15-seg on-and-off cycles at 4&#x000b0;C. After sonication, the lysate was then centrifugated at 27000 <italic>g</italic> for 20 min to obtain the protein pellet inclusion body. This pellet was dissolved in buffer containing 50 mM sodium phosphate, pH 6,0, 500 mM NaCl, 1 mM &#x003b2;-mercaptoethanol, 5% glycerol, 10 mM imidazol and 8 M urea, overnight stirring at 4&#x000b0;C. The cleared lysate was loaded onto a HisTrap HP column connected to the &#x000c4;kta Purifier HPLC. Proteins were eluted with a linear gradient of imidazole (10&#x02013;500 mM) prepared in the same buffer composition and the purified nucleoprotein was refolded by dialysis using a cut-off pore of MWCO of 3,500 Da and the same buffer composition during overnight at 4&#x000b0;C, making three changes using 1-L buffer each time. Recombinant SHNP or JHNP (rSHNP and rJHNP, respectively) were obtained with high purity and yield as analyzed by 15% SDS-PAGE and, as expected, a unique band of about 50 kDa was observed. The refolding process of the rSHNP or rJHNP was confirmed by fluorescence spectroscopy, which was used to monitor the intrinsic tryptophan fluorescence in the buffer containing 8M urea and after the dialysis process.</p></sec><sec id="sec011"><title>Ethics statement</title><p>This study was conducted in accordance with the Brazilian National Animal Care Ethical Council. All experiments were approved and permitted by the Ethics Committee for Animal Experimentation of the Oswaldo Cruz Foundation (CEUA-FIOCRUZ, Protocol N&#x000b0; LW-13/16).</p></sec><sec id="sec012"><title>Experimental mice immunization</title><p>BALB/c mice (6 weeks old; n = 6) were injected intraperitoneally at day 0 with an emulsion (1:1) containing 50 &#x003bc;g of purified rSHNP or rJHNP, expressed in <italic>Escherichia coli</italic>, in a final volume of 100 &#x003bc;L with complete Freund&#x000b4;s adjuvant (CFA). Fourteen and twenty-eight days after initial immunization, mice were re-injected intraperitoneally with an emulsion (1:1) containing 50 &#x003bc;g of purified rSHNP or rJHNP in a final volume of 100 &#x003bc;L with incomplete Freund&#x000b4;s adjuvant (IFA).</p></sec><sec id="sec013"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p>Mice IgG serum titration were assayed at 21 and 35 days after initial immunization using indirect ELISA against rSHNP or rJHNP or B-cell epitopes (SHNP<sub>(G72-D110)</sub>, SHNP<sub>(P251-D264)</sub> and SHNP<sub>(I266-A283)</sub>). Briefly, MaxiSorp 96-well plates (Nunc, Rochester, NY, USA) were coated with PBS containing 10 &#x003bc;g/mL of rSHNP or rJHNP or synthetized peptides (SHNP<sub>(G72-D110)</sub>, SHNP<sub>(P251-D264)</sub> and SHNP<sub>(I266-A283)</sub>). After overnight incubation at 4&#x000b0;C, the plates were washed and blocked for 1 h at 37&#x000b0;C with PBS 5% non-fat dry milk (PBS-5%M). Mice plasma samples were three-fold serial diluted in PBS-5%M, starting at 1:50, and added in duplicate wells. After 2 h at 37&#x000b0;C and three washings with PBS-5%M, bound antibodies were detected with peroxidase-conjugated goat anti mouse IgG (Sigma, St. Louis; 1:10000 dilution) and followed by addition of 3,3&#x02032;,5,5&#x02032;-tetramethylbenzidine. Optical density was measured at 450 nm using a SpectraMax microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). The IgG serum title was calculated interpolating the value of optical density unit of three times the pre-immune serum (3xPIS) on a linear regression graphic of serum dilution, using the mean optical density of each diluted sera in duplicate.</p></sec><sec id="sec014"><title>Collection of the templates, <italic>in silico</italic> homology modeling and model optimization</title><p>The rationale used for template selection and <italic>in silico</italic> homology modeling of SHNP was described by Lima et al. (2016) [<xref rid="pntd.0007915.ref023" ref-type="bibr">23</xref>] and carried out with some adaptations. Briefly, for the selection of templates, a search with BLAST and HHBlits [<xref rid="pntd.0007915.ref024" ref-type="bibr">24</xref>, <xref rid="pntd.0007915.ref025" ref-type="bibr">25</xref>] using the amino acid sequence of SHNP (GenBank: AAT45728.1) was performed against the expasy SWISS-MODEL template server [<xref rid="pntd.0007915.ref026" ref-type="bibr">26</xref>][<xref rid="pntd.0007915.ref002" ref-type="bibr">2</xref>][<xref rid="pntd.0007915.ref002" ref-type="bibr">2</xref>]. Three structures were selected (PDB ID: 5E04, 5FSG, 4FI5) with the view to obtain as close as possible complete coverage of the amino acid sequence. The server-generated models, which were built and based on the target-template alignment with ProMod3 Version 1.2.0 [<xref rid="pntd.0007915.ref027" ref-type="bibr">27</xref>], were used to perform the 2D alignment with the sequence of SHNP and comparative modeling using MODELLERv9.19 by satisfaction of spatial restraints [<xref rid="pntd.0007915.ref028" ref-type="bibr">28</xref>]. The lowest energy model was selected using PyMOL Version 1.8 and your 3D structure evaluated with Verify 3D [<xref rid="pntd.0007915.ref029" ref-type="bibr">29</xref>, <xref rid="pntd.0007915.ref030" ref-type="bibr">30</xref>] and MolProbity [<xref rid="pntd.0007915.ref031" ref-type="bibr">31</xref>]. The energy minimization and correction of Ramachandran outliers was performed manually using COOT Version 0.8.6 [<xref rid="pntd.0007915.ref032" ref-type="bibr">32</xref>].</p></sec></sec><sec sec-type="results" id="sec015"><title>Results</title><sec id="sec016"><title><italic>In silico</italic> analysis of Seoul Hantavirus Nucleoprotein (SHNP)</title><p>To predict linear B-cell epitopes with potential antigenicity, the full sequence of SHNP (NCBI ID: AAT45728.1) was analyzed by the BepiPred 2.0 and Vaxijen algorithms. As showed in <bold><xref rid="pntd.0007915.t001" ref-type="table">Table 1</xref></bold>, nine sequences (SHNP<sub>(K30-E48)</sub>; SHNP<sub>(G72-D110)</sub>; SHNP<sub>(G145-K173)</sub>; SHNP<sub>(P182-G196)</sub>; SHNP<sub>(D231-G141)</sub>; SHNP<sub>(P251-D264)</sub>; SHNP<sub>(T347-F361)</sub>; SHNP<sub>(Q363-I380)</sub>; SHNP<sub>(D394-E405)</sub>) presented BepiPred and Vaxijen Scores above threshold values (0.5 and 0.4, respectively) were predicted as antigenic linear B-cell epitopes in SHNP. Among sequences predicted as B-cell epitope by BepiPred 2.0, only SHNP<sub>(E5-V29)</sub> and SHNP<sub>(D231-G141)</sub> were predicted as non-antigenic epitopes by Vaxijen and were excluded of further analyzes.</p><table-wrap id="pntd.0007915.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007915.t001</object-id><label>Table 1</label><caption><title>Potential predicted B-cell epitopes of SHNP.</title></caption><alternatives><graphic id="pntd.0007915.t001g" xlink:href="pntd.0007915.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Predicted<break/>Epitope</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Sequence</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Position</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">BepiPred<break/>Score</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Vaxijen<break/>Score</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">SHNP<sub>(E5-V29)</sub></td><td align="justify" style="background-color:#FFFFFF" rowspan="1" colspan="1">EEIQREISAHEGQLV</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">5&#x02013;29</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.508</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.041</td></tr><tr><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(K30-E48)</bold></sub></td><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>KQYEKDPDDLNKRALHDRE</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>30&#x02013;48</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>0.506</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>0.666</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(G72-D110)</bold></sub></td><td align="justify" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>GKNIGQDRDPTGVEPGDHLKERSALSYGNTLDLNSLDID</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>72&#x02013;110</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>0.542</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>0.802</bold></td></tr><tr><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(G145-K173)</bold></sub></td><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>GRQTSKDNKGMRIRFKDDSSYEDVNGIRK</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>145&#x02013;173</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>0.511</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>0.652</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(P182-G196)</bold></sub></td><td align="justify" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>PNAQSSMKAEEITPG</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>182&#x02013;196</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>0.546</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>1.126</bold></td></tr><tr><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1">SHNP<sub>(D231-G141)</sub></td><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1">DWTSRIEEWLG</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">231&#x02013;241</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">0.521</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">0.237</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(P251-D264)</bold></sub></td><td align="justify" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>PIAGSLSGNPVNRD</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>251&#x02013;264</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>0.519</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>0.617</bold></td></tr><tr><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(I266-A283)</bold></sub></td><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>IRQRQGALAGMEPKEFQA</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>264&#x02013;283</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>0.518</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>1.21</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(T347-F361)</bold></sub></td><td align="justify" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>TVGTADEKLRKKSSF</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>347&#x02013;361</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>0.515</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>1.23</bold></td></tr><tr><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(Q363-I380)</bold></sub></td><td align="justify" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>QSYLRRTQSMGIQLDQRI</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>363&#x02013;380</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>0.544</bold></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><bold>0.723</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(D394-E405)</bold></sub></td><td align="justify" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>DNFHLGDDMDPE</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>394&#x02013;405</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>0.512</bold></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>1.073</bold></td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec017"><title>The major of predicted B-cell epitopes in HNSP were highly conserved among orthohantaviruses</title><p>Nucleoprotein is a conserved protein among orthohantavirus, presenting similarity level ranging from 60% to 99%. However, when compared to orthohantavirus related to HCPS (Juquitiba genotype, Andes virus, Laguna-Negra virus and Sin Nombre virus), the nucleoprotein from orthohantavirus related to HFRS (Gou, Hantaan, Amur, Dobrava-Belgrade and Puumala) were only intermediary conserved, ranging from 62% to 74% of similarity (<xref ref-type="supplementary-material" rid="pntd.0007915.s001">S1 Table</xref>).</p><p>Based on this variable degree of conservation of nucleoprotein and aiming to identify immunodominants B-cell epitopes specific to orthohantaviruses related to HFRS, we compare the similarity level of SHNP predicted epitopes among nucleoproteins of HFRS Hantavirus and HCPS Hantavirus. The levels of similarity were classified as very low (&#x0003c;25%;); low (25%&#x0003e;X&#x0003e;50%), intermediary (50%&#x0003c;X&#x0003c;75%) and high (75%&#x0003c;X&#x0003c;100%).</p><p>The similarity level observed among the epitopes of each orthohantavirus compared was shown in <xref rid="pntd.0007915.t002" ref-type="table"><bold>Table</bold> 2</xref>. Firstly, when compared to other orthohantavirus nucleoproteins, while SHNP presented only intermediary and high similarity levels (62% to 99%), we found B-cell epitopes from very low to high similarity (11% to 100%). The majority of predicted linear B-cell epitopes on SHNP were highly conserved in comparison with orthohantavirus associated with HFRS and to orthohantavirus associated with HCPS. The epitopes SHNP<sub>(G145-K173)</sub>, SHNP<sub>(P182-G196)</sub>, SHNP<sub>(T347-F361)</sub>, SHNP<sub>(Q363-I380)</sub>, SHNP<sub>(D394-E405)</sub> presented an conservation degree ranged from 67% to 100%, being the sequence SHNP<sub>(Q363-I380)</sub> the most conserved epitope, with an similarity level of 100% when compared to the most of orthohantavirus associated to HFRS and 94% when compared to virus or isolates associated with HCPS (<xref rid="pntd.0007915.t002" ref-type="table">Table 2</xref>). Besides, the predicted epitopes SHNP<sub>(K30-E48)</sub> and SHNP<sub>(G72-D110)</sub> presented high conservation degrees (ranged from 84% to 95% and 77% to 97%, respectively) in comparison with to the most of orthohantaviruses associated to HFRS and intermediary degree (ranged from 47% to 53% and 51% to 56%, respectively) when compared to sequences of virus or isolates associated to HCPS. Remarkably, the predicted epitopes SHNP<sub>(P182-G196)</sub> and SHNP<sub>(P251-D264)</sub> were considered specific to <italic>Seoul orthohantavirus</italic>, once both presenting 100% of similarity with Gou specie and low level of conservancy (ranged from 14% to 21% and 11%; respectively) in comparison with orthohantavirus associated HCPS.</p><table-wrap id="pntd.0007915.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007915.t002</object-id><label>Table 2</label><caption><title>Conservation degree of predicted antigenic linear B-cell epitopes among orthohantaviruses.</title></caption><alternatives><graphic id="pntd.0007915.t002g" xlink:href="pntd.0007915.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Related<break/>Syndrome</th><th align="center" colspan="5" rowspan="1">HFRS</th><th align="center" colspan="4" rowspan="1">HCPS</th></tr><tr><th align="center" rowspan="1" colspan="1">Hantavirus /<break/>Predicted epitopes</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">GOUV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">HTNV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">AMRV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">DOBV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">PUUV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">JUQV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">ANDV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">LANV</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">SNV</th></tr></thead><tbody><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">99%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">83%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">83%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">82%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">62%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">64%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">65%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">64%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">62%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(K30-E48)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">95%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">84%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">84%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">95%</td><td align="center" style="background-color:#A9D08E" rowspan="1" colspan="1">47%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">53%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">53%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">53%</td><td align="center" style="background-color:#A9D08E" rowspan="1" colspan="1">47%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(G72-D110)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">97%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">82%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">79%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">77%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">59%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">51%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">56%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">56%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">56%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(G145-K173)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">97%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">90%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">90%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">93%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">76%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">86%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">86%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">83%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">86%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(P182-G196)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">93%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">80%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">87%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">87%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">80%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">80%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(P251-D264)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#A9D08E" rowspan="1" colspan="1">36%</td><td align="center" style="background-color:#A9D08E" rowspan="1" colspan="1">29%</td><td align="center" style="background-color:#A9D08E" rowspan="1" colspan="1">29%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">21%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">14%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">14%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">21%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">14%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(I266-A283)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">61%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">61%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">72%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">17%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">11%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">11%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">11%</td><td align="center" style="background-color:#BFBFBF" rowspan="1" colspan="1">11%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(T347-F361)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">87%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">87%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">80%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">87%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">73%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">73%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">73%</td><td align="center" style="background-color:#FFC000" rowspan="1" colspan="1">67%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(Q363-I380)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">94%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">94%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">94%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">94%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">94%</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><bold>SHNP</bold><sub><bold>(D394-E405)</bold></sub></td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">100%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">92%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">92%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">83%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">83%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">83%</td><td align="center" style="background-color:#F15D59" rowspan="1" colspan="1">83%</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Values express the percentage of similarity of Seoul orthohantavirus nucleoprotein (SHNP) and its predicted epitopes among orthohantaviruses associated to HFRS&#x02013;Gou (GOUV), Hantaan (HTNV), Amur (AMRV), Dobrava-Belgrade (DOBV) and Puumala (PUUV)&#x02014;and related to HCPS&#x02013;Juquitiba genotype (JUQV), Andes (ANDV), Laguna-Negra (LANV) and Sin Nombre virus (SNV). The levels of similarity were classified as very low (&#x0003c;25%; gray cells), low (25%&#x0003e;X&#x0003c;50%; green cells), intermediary (50%&#x0003c;X&#x0003c;75%; yellow cells) and high (75%&#x0003c;X&#x0003c;100%; red cells).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>Animals immunized with HNSP recombinant protein were able to recognize specific B-cell epitopes <italic>in silico</italic> identified in HNSP sequence</title><p>After <italic>in silico</italic> analyzes, sequences of epitopes SHNP<sub>(G72-D110)</sub>, SHNP<sub>(P251-D264)</sub> and SHNP<sub>(I266-A283)</sub> were synthetized as linear peptides and tested by ELISA against sera sample from BALB/c mice immunized with rSHNP. This step aimed to validate experimentally epitopes with low (SHNP<sub>(P251-D264)</sub>, SHNP<sub>(I266-A283)</sub>) and intermediary (SHNP<sub>(G72-D110)</sub>) conservation degree among orthohantavirus associated to HCPS. Firstly, we confirmed that rSHNP is immunogenic in animal models because immunized mice presented specific antibodies against it at 28 days after the first immunization (IgG titer: 336829 &#x000b1; 92407) and presented an increase of 2.5-fold in the IgG serum title against rSHNP after the third immunization (IgG titer: 855671 &#x000b1; 118257). In relation to the specific humoral response against predicted peptides, mice immunized with rSHNP elicited specific antibodies against peptides SHNP<sub>(G72-D110)</sub> and SHNP<sub>(P251-D264)</sub>. Both peptides, were specifically recognized, presenting similar levels of antibodies level in the first (anti-SHNP<sub>(G72-D110)</sub> IgG titer: 5925 &#x000b1; 2747; anti-SHNP<sub>(P251-D264)</sub> IgG titer: 1604 &#x000b1; 1212) and second bleeding (anti-SHNP<sub>(G72-D110)</sub> IgG titer: 7550 &#x000b1; 1474 and anti-SHNP<sub>(P251-D264)</sub> IgG titer: 1911 &#x000b1; 1119). On the other hands, we did not observe any humoral response against SHNP<sub>(I266-A283)</sub> peptide (<xref ref-type="fig" rid="pntd.0007915.g001">Fig 1</xref>).</p><fig id="pntd.0007915.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007915.g001</object-id><label>Fig 1</label><caption><title>Kinetic of IgG serum title against rSHNP and predicted peptides after experimental immunization with rSHNP.</title><p>BALB/c mice (n = 3) were immunized with rSHNP emulsified with CFA at day 0 and rSHNP emulsified with IFA at day 14 and 28. IgG serum titer was evaluated by specific ELISA at days 21 and 35 (first and second bleeding). The IgG serum title was calculated interpolating the value of optical density unit of three times the pre-immune serum (3xPIS) on a linear regression graphic of serum dilution, using the mean optical density of each diluted sera in duplicate.</p></caption><graphic xlink:href="pntd.0007915.g001"/></fig></sec><sec id="sec019"><title>B-cell epitopes SHNP<sub>(G72-D110)</sub> and SHNP<sub>(P251-D264)</sub> were confirmed as highly specific to <italic>Seoul orthohantavirus</italic></title><p>In order to verify the specificity of predicted B-cell epitopes, the reactivity against rSHNP, rJHNP, SHNP<sub>(G72-D110),</sub> SHNP<sub>(P251-D264)</sub> and SHNP<sub>(I266-A283)</sub> were tested by ELISA against samples from mice immunized with both recombinant proteins, rSHNP and rJHNP and with non-immunized mice, at dilution of 1:100.</p><p>Initially, the immunization with rSHNP and rJHNP elicited a high cross reactivity, once that the immunizations results in similar recognize of recombinant proteins, rSHNP and rJHNP, by both immunized groups, immunized with rSHNP and immunized with rJHNP (<xref ref-type="fig" rid="pntd.0007915.g002">Fig 2</xref>). Despite this, considering the cut off value equal 3times the mean of non-immunized mice values, the epitopes SHNP<sub>(G72-D110)</sub> and SHNP<sub>(P251-D264)</sub> were highly specific to SHNP (Optical densities of 2.53 &#x000b1; 0.17 and 1.3 &#x000b1; 0.14, respectively) once that non-immunized mice (Optical densities: 0.08&#x000b1;0.011, p&#x0003c;0.0001 and 0.084&#x000b1;0.013, p&#x0003c;0.0001, respectively.) and mice immunized with rJHNP (Optical densities: 0.16&#x000b1;0.09, p&#x0003c;0.0001 and 0.084&#x000b1;0.006, p&#x0003c;0.0001, respectively) (<xref ref-type="fig" rid="pntd.0007915.g002">Fig 2</xref>). Besides, there no were statistical differences in response to SHNP<sub>(G72-D110)</sub> and SHNP<sub>(P251-D264)</sub> between non-immunized mice and rJHNP immunized mice.</p><fig id="pntd.0007915.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007915.g002</object-id><label>Fig 2</label><caption><title>Evaluation of cross reactivity against rSHNP, rJQNP, SHNP(G72-D110), SHNP(P251-D264) and SHNP(I266-A283) elicited by immunization with rSHNP and rJHNP.</title><p>Bars represent the optical densities of mice immunized with rSHNP (red bars, n = 3) and immunized with rJHNP (blue bars, n = 3) and non-immunized mice (green bars, n = 6). Traced line indicates the value of Cut-off, defined as 3 times the mean of non-immune optical densities. Data is presented as floating bars with lines indicate minimum, mean and maximum values. Values higher than cut-off were considered responder to antigen and compared by test-T against other groups. * represents difference between immunized groups and non-immunized mice, while + represents statistical differences between immunized groups.</p></caption><graphic xlink:href="pntd.0007915.g002"/></fig></sec><sec id="sec020"><title>Homology modeling</title><p>Search of homologous SHNP structures (GenBank: AAT45728.1) were carried out using the SWISS-MODEL server, using information from Protein Data bank (PDB), and resulted in three protein structures which were used for homology modeling: 5FSG, 4FI5 and 5E04 with sequence identity of 82.91%, 84.62% and 66.08%, respectively. The complete template description is shown in <bold><xref rid="pntd.0007915.t003" ref-type="table">Table 3</xref></bold>.</p><table-wrap id="pntd.0007915.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007915.t003</object-id><label>Table 3</label><caption><title>Summary of the templates used for homology modeling of SHNP.</title></caption><alternatives><graphic id="pntd.0007915.t003g" xlink:href="pntd.0007915.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Template</th><th align="center" rowspan="1" colspan="1">Seq. Identity</th><th align="center" rowspan="1" colspan="1">Found by</th><th align="center" rowspan="1" colspan="1">Method</th><th align="center" rowspan="1" colspan="1">Resolution</th><th align="center" rowspan="1" colspan="1">Coverage</th><th align="center" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1"><bold>5FSG</bold></td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">82.91</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">HHblits</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">X-ray</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">3.21&#x000c5;</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">0.74</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">Maltose-binding periplasmic protein, orthohantavirus nucleoprotein</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>4FI5</bold></td><td align="center" rowspan="1" colspan="1">84.62</td><td align="center" rowspan="1" colspan="1">BLAST</td><td align="center" rowspan="1" colspan="1">X-ray</td><td align="center" rowspan="1" colspan="1">2.20&#x000c5;</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">Nucleoprotein</td></tr><tr><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1"><bold>5E04</bold></td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">66.08</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">HHblits</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">X-ray</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">2.25&#x000c5;</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">0.66</td><td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">Nucleoprotein</td></tr></tbody></table></alternatives></table-wrap><p>From the alignment of the target sequence with the template sequences, 200 models were built and the lowest energy model was selected. The Molprobity server and WinCoot software was used to evaluate the stereochemical quality of the selected model from Ramachandran plots. After energy minimization, it was possible to reach 97.19% (415/427) of residues in preferred regions, 2.58% (11/427) in allowed regions and only 0.23% (1/427)&#x02013; 114 GLY&#x02014;outliers in Ramachandran graph. The 3D structure of the model presented a score of 75.52% on Verify 3D, which demonstrates the quality of the model obtained.</p><p>SHNP homology model and the prediction of its electrostatic surface are shown in Figs <xref ref-type="fig" rid="pntd.0007915.g003">3A</xref> and <xref ref-type="fig" rid="pntd.0007915.g002">2B</xref>. The spatial location and shape of predicted linear peptides&#x02014;SHNP<sub>(G72-D110)</sub> (<xref ref-type="fig" rid="pntd.0007915.g003">Fig 3C</xref>), SHNP<sub>(P251-D264)</sub> (<xref ref-type="fig" rid="pntd.0007915.g003">Fig 3D</xref>) and SHNP<sub>(I266-A283)</sub> (<xref ref-type="fig" rid="pntd.0007915.g003">Fig 3E</xref>)&#x02014;were demonstrated in the model generated. When performing an analysis of the location of the peptides in front of the electrostatic surface of the predicted protein, it is possible to verify that the peptide SHNP<sub>(G72-D110)</sub> (<xref ref-type="fig" rid="pntd.0007915.g003">Fig 3C</xref>) is at a more electronegative region (red) than SHNP<sub>(P251-D264)</sub> (<xref ref-type="fig" rid="pntd.0007915.g003">Fig 3D</xref>) and SHNP<sub>(I266-A283)</sub> (<xref ref-type="fig" rid="pntd.0007915.g003">Fig 3E</xref>) peptides, which are in a more neutral/electropositive region.</p><fig id="pntd.0007915.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007915.g003</object-id><label>Fig 3</label><caption><title>Predicted SHNP homology model.</title><p>(A) SHNP representation as cartoon with predicted linear peptides spatial localization represented by colors where: red&#x02014;SHNP<sub>(G72-D110)</sub>; green&#x02014;SHNP<sub>(P251-D264)</sub>; yellow&#x02014;SHNP<sub>(I266-A283)</sub>. (B) SHNP electrostatic potential surface representing the positive (blue) and negative (red) charges of predicted protein. Peptides sticks representations of SHNP<sub>(G72-D110)</sub> (C), SHNP<sub>(P251-D264)</sub> (D), SHNP<sub>(I266-A283)</sub> (E) and their respective locations and electrostatic characteristics on the protein surface; SHNP<sub>(G72-D110)</sub> is in a more electronegative region whereas SHNP<sub>(P251-D264)</sub> and SHNP<sub>(I266-A283)</sub> are found in regions with more neutral features.</p></caption><graphic xlink:href="pntd.0007915.g003"/></fig></sec></sec><sec sec-type="conclusions" id="sec021"><title>Discussion</title><p>Orthohaantavirus species associated with hemorrhagic fevers are worldwide spread; however, they could be misdiagnose as viral or bacterial hemorrhagic diseases, like dengue, yellow fever or leptospirosis, especially in countries where these diseases are endemic. In this context, the development of novel, specific and broader diagnostic tools, able to recognized HFRS-associated orthohantavirus species, have become an urgent demand to public health. Immunodiagnostic tools are vital in the study of orthohantavirus infections due to the limited success with molecular detection as the viremia will be short-lived. Based on this, our study allowed the <italic>in silico</italic> identification and experimental confirmation of two B-cell linear epitopes on SHNP. These data could be helpful to improve the development of new diagnostic tools, resulting in a better and more specific HFRS-associated orthohantavirus diagnose, especially in the New World.</p><p>Recently, Kalaiselvan and collaborators suggested that 20-mers peptides <italic>in silico</italic> identified as B-cell linear epitopes may be used for development of geographic region-specific immunoassays [<xref rid="pntd.0007915.ref016" ref-type="bibr">16</xref>], however, the experimental validation of predicted epitopes remains pending. Based on this study, we explored the nucleoprotein of <italic>Seoul orthohantavirus</italic>, using a combination of <italic>in silico</italic> approaches to predict antigenic B-cell linear epitopes, non-conserved among hantaviruses associated to HCPS, and to validate its immunogenicity by the reactivity of serum samples from mice immunized with the recombinant protein. Initially, we predicted nine sequences as immunogenic epitopes, in which eight (88.9%) were, entirely or partially, inserted on sequences described in Kalaiselvan&#x02019;s study [<xref rid="pntd.0007915.ref016" ref-type="bibr">16</xref>]. In our point of view, the differences observed between our and his study about predicted epitopes were due the use of BepiPred 1.0, by Kalaiselvan, and BepiPred 2.0, by us. However, the high congruence of both studies reinforces the use of prediction algorithms to identify B-cell epitopes on proteins and remarks the necessity of experimental validation of these results.</p><p>Aiming to identify epitopes non-conserved among HCPS orthohantavirus, we compared the conservation of each predicted sequence among orthohantaviruses associated to HFRS and HCPS. The epitopes SHNP<sub>(K30-E48)</sub>, SHNP<sub>(G72-D110)</sub>, and SHNP<sub>(I266-A283)</sub> were highly conserved just among species associated to HFRS, presenting a conservation level ranging from moderate to low, when compared to HCPS orthohantavirus species. Besides, the epitope SHNP<sub>(P251-D264)</sub> was considered specific epitope of <italic>Seoul orthohantavirus</italic>, presenting a very high similarity when compared with Gou (100%) and low conservancies (&#x0003c;36%) in comparison with species associated to HCPS or HFRS. Remarkably, all epitopes considered non-conserved among HCPS orthohantavirus (SHNP<sub>(K30-E48)</sub>, SHNP<sub>(G72-D110)</sub>, SHNP<sub>(P251-D264)</sub> and SHNP<sub>(I266-A283)</sub>) presented low to moderate conservation degrees, ranging from 17% to 59%, when compared with Puumala nucleoprotein sequence. Despite of the association of this orthohantavirus specie with HFRS [<xref rid="pntd.0007915.ref033" ref-type="bibr">33</xref>&#x02013;<xref rid="pntd.0007915.ref035" ref-type="bibr">35</xref>], <italic>Puumala orthohantavirus</italic> was also associated with HCPS [<xref rid="pntd.0007915.ref036" ref-type="bibr">36</xref>] and is considered the most prevalent pathogen associated with nephropathia epidemica [<xref rid="pntd.0007915.ref037" ref-type="bibr">37</xref>], a mild form of HFRS. This epidemics is characterized by acute kidney injury (AKI) and thrombocytopenia [<xref rid="pntd.0007915.ref005" ref-type="bibr">5</xref>], suggesting differences among species associated to HFRS. Besides, we observed that major of predicted sequences were highly conserved among orthohantavirus associated to both syndromes, HFRS and HCPS. Our data corroborate Kalaiselvan&#x02019;s previous studies [<xref rid="pntd.0007915.ref016" ref-type="bibr">16</xref>, <xref rid="pntd.0007915.ref017" ref-type="bibr">17</xref>], in which epitopes conserved between both orthohantavirus species, HFRS and HCPS, were <italic>in silico</italic> predicted with prevalence in C-terminal region of the nucleoprotein.</p><p>Despite the increasing use of <italic>in silico</italic> approaches to predict epitopes against several diseases, the experimental validation of predicted sequences remains scarce, despite being a critical step to the development of novel vaccines and diagnostic tools. In this context, this was the first study reporting the experimental validation of specific B-cell linear epitopes against orthohantavirus, resulting in the recognition of SHNP<sub>(G72-D110)</sub> and SHNP<sub>(P251-D264)</sub> epitopes as promising targets to further development of monoclonal antibodies and/or highly-specific tools to HFRS orthohantavirus diagnosis. Moreover, about the non-reactivity of predicted epitope SHNP<sub>(I266-A283)</sub> and considering the use of <italic>in silico</italic> strategies to select B-cell epitopes, the oligomerization mode of selected target seems to be an important aspect to epitope selection. Here, we initially predicted three specifics B-cell epitopes in HFRS orthohantavirus and evaluated their localization in tertiary monomeric structure of SHNP, considering all epitopes exposed in protein surface. Controversially, considering that nucleoprotein oligomerizes in dimeric or hexameric forms [<xref rid="pntd.0007915.ref003" ref-type="bibr">3</xref>, <xref rid="pntd.0007915.ref038" ref-type="bibr">38</xref>], we believed that the non-reactivity of epitope SHNP<sub>(I266-A283)</sub> could be explained by its localization in quaternary structure.</p><p>Currently, orthohantavirus commercial serological kits are based on nucleoprotein detection however the cross-reactivity among hosts infected by HCPS and/or HFRS-associated orthohantavirus could not be discarded. In our study, we experimentally immunized mice with recombinant nucleoprotein from Juquitiba genotype, a HCPS-associated orthohantavirus that mainly circulates in Brazil [<xref rid="pntd.0007915.ref039" ref-type="bibr">39</xref>, <xref rid="pntd.0007915.ref040" ref-type="bibr">40</xref>], eliciting a polyclonal response able to generate antibodies that recognized JHNP and SHNP (<bold><xref ref-type="fig" rid="pntd.0007915.g002">Fig 2</xref></bold>). Based on this cross reaction and considering that Juquitiba genotype nucleoprotein is highly conserved among ANDV and SNV (95% and 86% of similarity, respectively), both orthohantavirus associated to HCPS in Americas, we believe that Juquitiba genotype could be used as HCPS model. Remarkably, despite the cross reaction among JHNP and SHNP, we identify epitopes specific to <italic>Seoul orthohantavirus</italic>. SHNP<sub>(G72-D110)</sub> and SHNP<sub>(P251-D264)</sub> epitopes were only recognized by sera from SHNP immunized mice, suggesting that these epitopes are non-conserved among HCPS-associated orthohantavirus and corroborating their potential as HFRS target. This strategy, based on experimental immunization assays using recombinant proteins, have been used to confirm <italic>in silico</italic> findings [<xref rid="pntd.0007915.ref041" ref-type="bibr">41</xref>&#x02013;<xref rid="pntd.0007915.ref044" ref-type="bibr">44</xref>], however, considering the probable misdiagnose of <italic>Seoul orthohantavirus</italic> in Americas and the necessity of differential diagnosis of HFRS in New world, experiments using samples of naturally infected hosts (human and/or rodents) should be conducted in order to fully support the present data and to confirm the real potential of these epitopes as differential diagnostic tools.</p><p>In summary, we <italic>in silico</italic> identified and experimentally validated the sequences (72)GKNIGQDRDPTGVEPGDHLKERSALSYGNTLDLNSLDID(110) and (251)PIAGSLSGNPVNRD(264) as linear B-cell epitopes on SHNP, which could be helpful to improve the development of novel immunodiagnostic tools against HFRS-associated orthohantavirus species. These epitopes, as synthetic peptides, could be anchored on solid surface or membranes for enzyme immunoassays; or used in the development of monoclonal antibodies, applicable to tools like sandwich ELISA, immunohistochemistry and immunofluorescence tests, which may be relevant to better and more specific HFRS-associated orthohantavirus diagnose, especially in the New World.</p></sec><sec sec-type="supplementary-material" id="sec022"><title>Supporting information</title><supplementary-material content-type="local-data" id="pntd.0007915.s001"><label>S1 Table</label><caption><title>Comparison of nucleoproteins similarity among hantavirus.</title><p>Values express the percentage of similarity of <italic>Seoul orthohantavirus</italic> nucleoprotein (SHNP) and its predicted epitopes among orthohantaviruses associated to HFRS&#x02013;Gou (GOUV), Hantaan (HTNV), Amur (AMRV), Dobrava-Belgrade (DOBV) and Puumala (PUUV)&#x02014;and related to HCPS&#x02013;Juquitiba genotype (JUQV), Andes (ANDV), Laguna-Negra (LANV) and Sin Nombre virus (SNV). The levels of similarity were classified as intermediary (50%&#x0003c;X&#x0003c;75%; orange cells) and high (75%&#x0003c;X&#x0003c;100%; red cells).</p><p>(DOCX)</p></caption><media xlink:href="pntd.0007915.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pntd.0007915.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>PZ</given-names></name>, <name><surname>Yu</surname><given-names>HT</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>K</given-names></name>, <name><surname>Du</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Development of a SYBR Green I based one-step real-time PCR assay for the detection of Hantaan virus</article-title>. <source>J Virol Methods</source>. <year>2014</year>;<volume>196</volume>:<fpage>145</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2013.11.004</pub-id> .<?supplied-pmid 24269331?><pub-id pub-id-type="pmid">24269331</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Vaheri</surname><given-names>A</given-names></name>, <name><surname>Strandin</surname><given-names>T</given-names></name>, <name><surname>Hepojoki</surname><given-names>J</given-names></name>, <name><surname>Sironen</surname><given-names>T</given-names></name>, <name><surname>Henttonen</surname><given-names>H</given-names></name>, <name><surname>Makela</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Uncovering the mysteries of hantavirus infections</article-title>. <source>Nat Rev Microbiol</source>. <year>2013</year>;<volume>11</volume>(<issue>8</issue>):<fpage>539</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3066</pub-id> .<?supplied-pmid 24020072?><pub-id pub-id-type="pmid">24020072</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Olal</surname><given-names>D</given-names></name>, <name><surname>Daumke</surname><given-names>O</given-names></name>. <article-title>Structure of the Hantavirus Nucleoprotein Provides Insights into the Mechanism of RNA Encapsidation</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>14</volume>(<issue>9</issue>):<fpage>2092</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.02.005</pub-id> .<?supplied-pmid 26923588?><pub-id pub-id-type="pmid">26923588</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Amada</surname><given-names>T</given-names></name>, <name><surname>Yoshimatsu</surname><given-names>K</given-names></name>, <name><surname>Yasuda</surname><given-names>SP</given-names></name>, <name><surname>Shimizu</surname><given-names>K</given-names></name>, <name><surname>Koma</surname><given-names>T</given-names></name>, <name><surname>Hayashimoto</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Rapid, whole blood diagnostic test for detecting anti-hantavirus antibody in rats</article-title>. <source>J Virol Methods</source>. <year>2013</year>;<volume>193</volume>(<issue>1</issue>):<fpage>42</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2013.04.021</pub-id> .<?supplied-pmid 23684845?><pub-id pub-id-type="pmid">23684845</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>H</given-names></name>, <name><surname>Zheng</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Du</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <name><surname>Bai</surname><given-names>X</given-names></name>. <article-title>Hantavirus infection: a global zoonotic challenge</article-title>. <source>Virol Sin</source>. <year>2017</year>;<volume>32</volume>(<issue>1</issue>):<fpage>32</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/s12250-016-3899-x</pub-id> .<?supplied-pmid 28120221?><pub-id pub-id-type="pmid">28120221</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HW</given-names></name>. <article-title>Hemorrhagic fever with renal syndrome (HFRS)</article-title>. <source>Scand J Infect Dis Suppl</source>. <year>1982</year>;<volume>36</volume>:<fpage>82</fpage>&#x02013;<lpage>5</lpage>. .<?supplied-pmid 6134332?><pub-id pub-id-type="pmid">6134332</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>LeDuc</surname><given-names>JW</given-names></name>, <name><surname>Smith</surname><given-names>GA</given-names></name>, <name><surname>Pinheiro</surname><given-names>FP</given-names></name>, <name><surname>Vasconcelos</surname><given-names>PF</given-names></name>, <name><surname>Rosa</surname><given-names>ES</given-names></name>, <name><surname>Maiztegui</surname><given-names>JI</given-names></name>. <article-title>Isolation of a Hantaan-related virus from Brazilian rats and serologic evidence of its widespread distribution in South America</article-title>. <source>Am J Trop Med Hyg</source>. <year>1985</year>;<volume>34</volume>(<issue>4</issue>):<fpage>810</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.1985.34.810</pub-id> .<?supplied-pmid 2862803?><pub-id pub-id-type="pmid">2862803</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Clement</surname><given-names>J</given-names></name>, <name><surname>LeDuc</surname><given-names>JW</given-names></name>, <name><surname>Lloyd</surname><given-names>G</given-names></name>, <name><surname>Reynes</surname><given-names>JM</given-names></name>, <name><surname>McElhinney</surname><given-names>L</given-names></name>, <name><surname>Van Ranst</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Wild Rats, Laboratory Rats, Pet Rats: Global Seoul Hantavirus Disease Revisited</article-title>. <source>Viruses</source>. <year>2019</year>;<volume>11</volume>(<issue>7</issue>). <pub-id pub-id-type="doi">10.3390/v11070652</pub-id>
<?supplied-pmid 31319534?><pub-id pub-id-type="pmid">31319534</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Costa</surname><given-names>F</given-names></name>, <name><surname>Porter</surname><given-names>FH</given-names></name>, <name><surname>Rodrigues</surname><given-names>G</given-names></name>, <name><surname>Farias</surname><given-names>H</given-names></name>, <name><surname>de Faria</surname><given-names>MT</given-names></name>, <name><surname>Wunder</surname><given-names>EA</given-names></name>, <etal>et al</etal>
<article-title>Infections by Leptospira interrogans, Seoul virus, and Bartonella spp. among Norway rats (Rattus norvegicus) from the urban slum environment in Brazil</article-title>. <source>Vector Borne Zoonotic Dis</source>. <year>2014</year>;<volume>14</volume>(<issue>1</issue>):<fpage>33</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1089/vbz.2013.1378</pub-id>
<?supplied-pmid 24359425?><pub-id pub-id-type="pmid">24359425</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Clement</surname><given-names>J</given-names></name>, <name><surname>Neild</surname><given-names>G</given-names></name>, <name><surname>Hinrichsen</surname><given-names>SL</given-names></name>, <name><surname>Crescente</surname><given-names>JA</given-names></name>, <name><surname>Van Ranst</surname><given-names>M</given-names></name>. <article-title>Urban leptospirosis versus urban hantavirus infection in Brazil</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>354</volume>(<issue>9194</issue>):<fpage>2003</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(05)76782-9</pub-id> .<?supplied-pmid 10622333?><pub-id pub-id-type="pmid">10622333</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Yoshimatsu</surname><given-names>K</given-names></name>, <name><surname>Arikawa</surname><given-names>J</given-names></name>. <article-title>Serological diagnosis with recombinant N antigen for hantavirus infection</article-title>. <source>Virus Res</source>. <year>2014</year>;<volume>187</volume>:<fpage>77</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2013.12.040</pub-id> .<?supplied-pmid 24487183?><pub-id pub-id-type="pmid">24487183</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Koma</surname><given-names>T</given-names></name>, <name><surname>Yoshimatsu</surname><given-names>K</given-names></name>, <name><surname>Pini</surname><given-names>N</given-names></name>, <name><surname>Safronetz</surname><given-names>D</given-names></name>, <name><surname>Taruishi</surname><given-names>M</given-names></name>, <name><surname>Levis</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Truncated hantavirus nucleocapsid proteins for serotyping Sin Nombre, Andes, and Laguna Negra hantavirus infections in humans and rodents</article-title>. <source>J Clin Microbiol</source>. <year>2010</year>;<volume>48</volume>(<issue>5</issue>):<fpage>1635</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00072-10</pub-id>
<?supplied-pmid 20335425?><pub-id pub-id-type="pmid">20335425</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Vapalahti</surname><given-names>O</given-names></name>, <name><surname>Kallio-Kokko</surname><given-names>H</given-names></name>, <name><surname>Narvanen</surname><given-names>A</given-names></name>, <name><surname>Julkunen</surname><given-names>I</given-names></name>, <name><surname>Lundkvist</surname><given-names>A</given-names></name>, <name><surname>Plyusnin</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Human B-cell epitopes of Puumala virus nucleocapsid protein, the major antigen in early serological response</article-title>. <source>J Med Virol</source>. <year>1995</year>;<volume>46</volume>(<issue>4</issue>):<fpage>293</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.1890460402</pub-id> .<?supplied-pmid 7595404?><pub-id pub-id-type="pmid">7595404</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Hujakka</surname><given-names>H</given-names></name>, <name><surname>Koistinen</surname><given-names>V</given-names></name>, <name><surname>Kuronen</surname><given-names>I</given-names></name>, <name><surname>Eerikainen</surname><given-names>P</given-names></name>, <name><surname>Parviainen</surname><given-names>M</given-names></name>, <name><surname>Lundkvist</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Diagnostic rapid tests for acute hantavirus infections: specific tests for Hantaan, Dobrava and Puumala viruses versus a hantavirus combination test</article-title>. <source>J Virol Methods</source>. <year>2003</year>;<volume>108</volume>(<issue>1</issue>):<fpage>117</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/s0166-0934(02)00282-3</pub-id> .<?supplied-pmid 12565162?><pub-id pub-id-type="pmid">12565162</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Hjelle</surname><given-names>B</given-names></name>, <name><surname>Jenison</surname><given-names>S</given-names></name>, <name><surname>Torrez-Martinez</surname><given-names>N</given-names></name>, <name><surname>Herring</surname><given-names>B</given-names></name>, <name><surname>Quan</surname><given-names>S</given-names></name>, <name><surname>Polito</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for field diagnosis</article-title>. <source>J Clin Microbiol</source>. <year>1997</year>;<volume>35</volume>(<issue>3</issue>):<fpage>600</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 9041397?><pub-id pub-id-type="pmid">9041397</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Kalaiselvan</surname><given-names>S</given-names></name>, <name><surname>Sankar</surname><given-names>S</given-names></name>, <name><surname>Ramamurthy</surname><given-names>M</given-names></name>, <name><surname>Ghosh</surname><given-names>AR</given-names></name>, <name><surname>Nandagopal</surname><given-names>B</given-names></name>, <name><surname>Sridharan</surname><given-names>G</given-names></name>. <article-title>Prediction of B Cell Epitopes Among Hantavirus Strains Causing Hemorragic Fever With Renal Syndrome</article-title>. <source>J Cell Biochem</source>. <year>2017</year>;<volume>118</volume>(<issue>5</issue>):<fpage>1182</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.25765</pub-id> .<?supplied-pmid 27748540?><pub-id pub-id-type="pmid">27748540</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Kalaiselvan</surname><given-names>S</given-names></name>, <name><surname>Sankar</surname><given-names>S</given-names></name>, <name><surname>Ramamurthy</surname><given-names>M</given-names></name>, <name><surname>Ghosh</surname><given-names>AR</given-names></name>, <name><surname>Nandagopal</surname><given-names>B</given-names></name>, <name><surname>Sridharan</surname><given-names>G</given-names></name>. <article-title>Prediction of Pan-Specific B-Cell Epitopes From Nucleocapsid Protein of Hantaviruses Causing Hantavirus Cardiopulmonary Syndrome</article-title>. <source>J Cell Biochem</source>. <year>2017</year>;<volume>118</volume>(<issue>8</issue>):<fpage>2320</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.25887</pub-id> .<?supplied-pmid 28106282?><pub-id pub-id-type="pmid">28106282</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Jespersen</surname><given-names>MC</given-names></name>, <name><surname>Peters</surname><given-names>B</given-names></name>, <name><surname>Nielsen</surname><given-names>M</given-names></name>, <name><surname>Marcatili</surname><given-names>P</given-names></name>. <article-title>BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>(<issue>W1</issue>):<fpage>W24</fpage>&#x02013;<lpage>W9</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx346</pub-id>
<?supplied-pmid 28472356?><pub-id pub-id-type="pmid">28472356</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Doytchinova</surname><given-names>IA</given-names></name>, <name><surname>Flower</surname><given-names>DR</given-names></name>. <article-title>VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines</article-title>. <source>BMC Bioinformatics</source>. <year>2007</year>;<volume>8</volume>:<fpage>4</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-8-4</pub-id>
<?supplied-pmid 17207271?><pub-id pub-id-type="pmid">17207271</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>TA</given-names></name>. <article-title>BioEdit: User-friendly biological sequence alignment editor and analysis program for windows 95/98/NT</article-title>. <source>Nucleic Acids Symposium Series</source>, Vol <volume>41</volume> (<issue>1999</issue>), pp <fpage>95</fpage>&#x02013;<lpage>98</lpage> Key: citeulike:691774. 1999;41:3.</mixed-citation></ref><ref id="pntd.0007915.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Luu</surname><given-names>T</given-names></name>, <name><surname>Pham</surname><given-names>S</given-names></name>, <name><surname>Deshpande</surname><given-names>S</given-names></name>. <article-title>Automated multiple peptide synthesis: improvements in obtaining quality peptides</article-title>. <source>Int J Pept Protein Res</source>. <year>1996</year>;<volume>47</volume>(<issue>1&#x02013;2</issue>):<fpage>91</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-3011.1996.tb00814.x</pub-id> .<?supplied-pmid 8907504?><pub-id pub-id-type="pmid">8907504</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Gausepohl</surname><given-names>H</given-names></name>, <name><surname>Boulin</surname><given-names>C</given-names></name>, <name><surname>Kraft</surname><given-names>M</given-names></name>, <name><surname>Frank</surname><given-names>RW</given-names></name>. <article-title>Automated multiple peptide synthesis</article-title>. <source>Pept Res</source>. <year>1992</year>;<volume>5</volume>(<issue>6</issue>):<fpage>315</fpage>&#x02013;<lpage>20</lpage>. .<?supplied-pmid 1283542?><pub-id pub-id-type="pmid">1283542</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Lima</surname><given-names>RN</given-names></name>, <name><surname>Faheem</surname><given-names>M</given-names></name>, <name><surname>Barbosa</surname><given-names>JA</given-names></name>, <name><surname>Poleto</surname><given-names>MD</given-names></name>, <name><surname>Verli</surname><given-names>H</given-names></name>, <name><surname>Melo</surname><given-names>FL</given-names></name>, <etal>et al</etal>
<article-title>Homology modeling and molecular dynamics provide structural insights into tospovirus nucleoprotein</article-title>. <source>BMC Bioinformatics</source>. <year>2016</year>;<volume>17</volume>(<issue>Suppl 18</issue>):<fpage>489</fpage>
<pub-id pub-id-type="doi">10.1186/s12859-016-1339-4</pub-id>
<?supplied-pmid 28105914?><pub-id pub-id-type="pmid">28105914</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Camacho</surname><given-names>C</given-names></name>, <name><surname>Coulouris</surname><given-names>G</given-names></name>, <name><surname>Avagyan</surname><given-names>V</given-names></name>, <name><surname>Ma</surname><given-names>N</given-names></name>, <name><surname>Papadopoulos</surname><given-names>J</given-names></name>, <name><surname>Bealer</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>BLAST+: architecture and applications</article-title>. <source>BMC Bioinformatics</source>. <year>2009</year>;<volume>10</volume>:<fpage>421</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-10-421</pub-id>
<?supplied-pmid 20003500?><pub-id pub-id-type="pmid">20003500</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Remmert</surname><given-names>M</given-names></name>, <name><surname>Biegert</surname><given-names>A</given-names></name>, <name><surname>Hauser</surname><given-names>A</given-names></name>, <name><surname>Soding</surname><given-names>J</given-names></name>. <article-title>HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment</article-title>. <source>Nat Methods</source>. <year>2011</year>;<volume>9</volume>(<issue>2</issue>):<fpage>173</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1818</pub-id> .<?supplied-pmid 22198341?><pub-id pub-id-type="pmid">22198341</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Biasini</surname><given-names>M</given-names></name>, <name><surname>Bienert</surname><given-names>S</given-names></name>, <name><surname>Waterhouse</surname><given-names>A</given-names></name>, <name><surname>Arnold</surname><given-names>K</given-names></name>, <name><surname>Studer</surname><given-names>G</given-names></name>, <name><surname>Schmidt</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information</article-title>. <source>Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume>(<issue>Web Server issue</issue>):<fpage>W252</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku340</pub-id>
<?supplied-pmid 24782522?><pub-id pub-id-type="pmid">24782522</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Guex</surname><given-names>N</given-names></name>, <name><surname>Peitsch</surname><given-names>MC</given-names></name>, <name><surname>Schwede</surname><given-names>T</given-names></name>. <article-title>Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective</article-title>. <source>Electrophoresis</source>. <year>2009</year>;<volume>30</volume>
<issue>Suppl 1</issue>:<fpage>S162</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/elps.200900140</pub-id> .<?supplied-pmid 19517507?><pub-id pub-id-type="pmid">19517507</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Sali</surname><given-names>A</given-names></name>, <name><surname>Blundell</surname><given-names>TL</given-names></name>. <article-title>Comparative protein modelling by satisfaction of spatial restraints</article-title>. <source>J Mol Biol</source>. <year>1993</year>;<volume>234</volume>(<issue>3</issue>):<fpage>779</fpage>&#x02013;<lpage>815</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1993.1626</pub-id> .<?supplied-pmid 8254673?><pub-id pub-id-type="pmid">8254673</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Bowie</surname><given-names>JU</given-names></name>, <name><surname>Luthy</surname><given-names>R</given-names></name>, <name><surname>Eisenberg</surname><given-names>D</given-names></name>. <article-title>A method to identify protein sequences that fold into a known three-dimensional structure</article-title>. <source>Science</source>. <year>1991</year>;<volume>253</volume>(<issue>5016</issue>):<fpage>164</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1126/science.1853201</pub-id> .<?supplied-pmid 1853201?><pub-id pub-id-type="pmid">1853201</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Luthy</surname><given-names>R</given-names></name>, <name><surname>Bowie</surname><given-names>JU</given-names></name>, <name><surname>Eisenberg</surname><given-names>D</given-names></name>. <article-title>Assessment of protein models with three-dimensional profiles</article-title>. <source>Nature</source>. <year>1992</year>;<volume>356</volume>(<issue>6364</issue>):<fpage>83</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/356083a0</pub-id> .<?supplied-pmid 1538787?><pub-id pub-id-type="pmid">1538787</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>VB</given-names></name>, <name><surname>Arendall</surname><given-names>WB</given-names><suffix>3rd</suffix></name>, <name><surname>Headd</surname><given-names>JJ</given-names></name>, <name><surname>Keedy</surname><given-names>DA</given-names></name>, <name><surname>Immormino</surname><given-names>RM</given-names></name>, <name><surname>Kapral</surname><given-names>GJ</given-names></name>, <etal>et al</etal>
<article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2010</year>;<volume>66</volume>(<issue>Pt 1</issue>):<fpage>12</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id>
<?supplied-pmid 20057044?><pub-id pub-id-type="pmid">20057044</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Emsley</surname><given-names>P</given-names></name>, <name><surname>Lohkamp</surname><given-names>B</given-names></name>, <name><surname>Scott</surname><given-names>WG</given-names></name>, <name><surname>Cowtan</surname><given-names>K</given-names></name>. <article-title>Features and development of Coot</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2010</year>;<volume>66</volume>(<issue>Pt 4</issue>):<fpage>486</fpage>&#x02013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id>
<?supplied-pmid 20383002?><pub-id pub-id-type="pmid">20383002</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Krautkramer</surname><given-names>E</given-names></name>, <name><surname>Nusshag</surname><given-names>C</given-names></name>, <name><surname>Baumann</surname><given-names>A</given-names></name>, <name><surname>Schafer</surname><given-names>J</given-names></name>, <name><surname>Hofmann</surname><given-names>J</given-names></name>, <name><surname>Schnitzler</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Clinical characterization of two severe cases of hemorrhagic fever with renal syndrome (HFRS) caused by hantaviruses Puumala and Dobrava-Belgrade genotype Sochi</article-title>. <source>BMC Infect Dis</source>. <year>2016</year>;<volume>16</volume>(<issue>1</issue>):<fpage>675</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-016-2012-2</pub-id>
<?supplied-pmid 27842513?><pub-id pub-id-type="pmid">27842513</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Cvetko</surname><given-names>L</given-names></name>, <name><surname>Markotic</surname><given-names>A</given-names></name>, <name><surname>Plyusnina</surname><given-names>A</given-names></name>, <name><surname>Margaletic</surname><given-names>J</given-names></name>, <name><surname>Miletic-Medved</surname><given-names>M</given-names></name>, <name><surname>Turk</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Puumala virus in Croatia in the 2002 HFRS outbreak</article-title>. <source>J Med Virol</source>. <year>2005</year>;<volume>77</volume>(<issue>2</issue>):<fpage>290</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.20448</pub-id> .<?supplied-pmid 16121366?><pub-id pub-id-type="pmid">16121366</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Alexeyev</surname><given-names>OA</given-names></name>, <name><surname>Elgh</surname><given-names>F</given-names></name>, <name><surname>Zhestkov</surname><given-names>AV</given-names></name>, <name><surname>Wadell</surname><given-names>G</given-names></name>, <name><surname>Juto</surname><given-names>P</given-names></name>. <article-title>Hantaan and Puumala virus antibodies in blood donors in Samara, an HFRS-endemic region in European Russia</article-title>. <source>Lancet</source>. <year>1996</year>;<volume>347</volume>(<issue>9013</issue>):<fpage>1483</fpage>
<pub-id pub-id-type="doi">10.1016/s0140-6736(96)91717-1</pub-id> .<?supplied-pmid 8676649?><pub-id pub-id-type="pmid">8676649</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Vollmar</surname><given-names>P</given-names></name>, <name><surname>Lubnow</surname><given-names>M</given-names></name>, <name><surname>Simon</surname><given-names>M</given-names></name>, <name><surname>Muller</surname><given-names>T</given-names></name>, <name><surname>Bergler</surname><given-names>T</given-names></name>, <name><surname>Alois</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Hantavirus cardiopulmonary syndrome due to Puumala virus in Germany</article-title>. <source>J Clin Virol</source>. <year>2016</year>;<volume>84</volume>:<fpage>42</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2016.10.004</pub-id> .<?supplied-pmid 27721108?><pub-id pub-id-type="pmid">27721108</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Manigold</surname><given-names>T</given-names></name>, <name><surname>Vial</surname><given-names>P</given-names></name>. <article-title>Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology</article-title>. <source>Swiss Med Wkly</source>. <year>2014</year>;<volume>144</volume>:<fpage>w13937</fpage>
<pub-id pub-id-type="doi">10.4414/smw.2014.13937</pub-id> .<?supplied-pmid 24652684?><pub-id pub-id-type="pmid">24652684</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Crystal Structure of the Core Region of Hantavirus Nucleocapsid Protein Reveals the Mechanism for Ribonucleoprotein Complex Formation</article-title>. <source>J Virol</source>. <year>2016</year>;<volume>90</volume>(<issue>2</issue>):<fpage>1048</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02523-15</pub-id>
<?supplied-pmid 26559827?><pub-id pub-id-type="pmid">26559827</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>de Araujo</surname><given-names>J</given-names></name>, <name><surname>Dure</surname><given-names>AI</given-names></name>, <name><surname>Negrao</surname><given-names>R</given-names></name>, <name><surname>Ometto</surname><given-names>T</given-names></name>, <name><surname>Thomazelli</surname><given-names>LM</given-names></name>, <name><surname>Durigon</surname><given-names>EL</given-names></name>. <article-title>Co-circulation in a single biome of the Juquitiba and Araraquara hantavirus detected in human sera in a sub-tropical region of Brazil</article-title>. <source>J Med Virol</source>. <year>2015</year>;<volume>87</volume>(<issue>5</issue>):<fpage>725</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.24118</pub-id> .<?supplied-pmid 25678450?><pub-id pub-id-type="pmid">25678450</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Figueiredo</surname><given-names>LT</given-names></name>, <name><surname>Souza</surname><given-names>WM</given-names></name>, <name><surname>Ferres</surname><given-names>M</given-names></name>, <name><surname>Enria</surname><given-names>DA</given-names></name>. <article-title>Hantaviruses and cardiopulmonary syndrome in South America</article-title>. <source>Virus Res</source>. <year>2014</year>;<volume>187</volume>:<fpage>43</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.01.015</pub-id> .<?supplied-pmid 24508343?><pub-id pub-id-type="pmid">24508343</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Bergmann-Leitner</surname><given-names>ES</given-names></name>, <name><surname>Chaudhury</surname><given-names>S</given-names></name>, <name><surname>Steers</surname><given-names>NJ</given-names></name>, <name><surname>Sabato</surname><given-names>M</given-names></name>, <name><surname>Delvecchio</surname><given-names>V</given-names></name>, <name><surname>Wallqvist</surname><given-names>AS</given-names></name>, <etal>et al</etal>
<article-title>Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>8</issue>):<fpage>e71610</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0071610</pub-id>
<?supplied-pmid 23977087?><pub-id pub-id-type="pmid">23977087</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Rezende</surname><given-names>CMF</given-names></name>, <name><surname>Coitinho</surname><given-names>JB</given-names></name>, <name><surname>Costa</surname><given-names>M</given-names></name>, <name><surname>Silva</surname><given-names>MR</given-names></name>, <name><surname>Giusta</surname><given-names>M</given-names></name>, <name><surname>Oliveira-Prado</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Biochemical analysis and identification of linear B-cell epitopes from recombinant Sm21.7 antigen from Schistosoma mansoni</article-title>. <source>Mol Immunol</source>. <year>2018</year>;<volume>101</volume>:<fpage>29</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2018.05.019</pub-id> .<?supplied-pmid 29857222?><pub-id pub-id-type="pmid">29857222</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Ti</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Lu</surname><given-names>Y</given-names></name>, <name><surname>Diao</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>. <article-title>Identification of one B-cell epitope from NS1 protein of duck Tembusu virus with monoclonal antibodies</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>7</issue>):<fpage>e0181177</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0181177</pub-id>
<?supplied-pmid 28746401?><pub-id pub-id-type="pmid">28746401</pub-id></mixed-citation></ref><ref id="pntd.0007915.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Rodrigues-da-Silva</surname><given-names>RN</given-names></name>, <name><surname>Correa-Moreira</surname><given-names>D</given-names></name>, <name><surname>Soares</surname><given-names>IF</given-names></name>, <name><surname>de-Luca</surname><given-names>PM</given-names></name>, <name><surname>Totino</surname><given-names>PRR</given-names></name>, <name><surname>Morgado</surname><given-names>FN</given-names></name>, <etal>et al</etal>
<article-title>Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>2</issue>):<fpage>306</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.10.016</pub-id> .<?supplied-pmid 30509693?><pub-id pub-id-type="pmid">30509693</pub-id></mixed-citation></ref></ref-list></back></article>